Kymera Therapeutics (KYMR) announced that it recently initiated dosing in the Phase 1 clinical trial in the US evaluating KT-621, a potent, selective, oral degrader of STAT6, in adult healthy volunteers. The Company expects to report Phase 1 data in the first half of 2025.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics announces three presentations at EOTC-NI-AACR
- Kymera Therapeutics announces FDA clearance of IND application for KT-621
- Kymera Therapeutics price target raised to $56 from $52 at Oppenheimer
- Kymera Therapeutics presents data for KT-621 at EADV Congress
- Kymera assumed with Outperform from Market Perform at Leerink